Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
19 February 2015 |
Main ID: |
NCT00195546 |
Date of registration:
|
13/09/2005 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
Study Evaluating DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause
|
Scientific title:
|
A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study of DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause |
Date of first enrolment:
|
April 2005 |
Target sample size:
|
465 |
Recruitment status: |
Completed |
URL:
|
http://clinicaltrials.gov/show/NCT00195546 |
Study type:
|
Interventional |
Study design:
|
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment
|
Phase:
|
Phase 3
|
|
Countries of recruitment
|
Belgium
|
Croatia
|
Czech Republic
|
Finland
|
France
|
Hungary
|
Mexico
|
Netherlands
|
Poland
|
Romania
|
South Africa
|
Spain
|
Sweden
|
Ukraine
|
United Kingdom
| |
Contacts
|
Name:
|
Trial Manager |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
For Hungary, Croatia, WPBUMED@wyeth.com |
|
Name:
|
Medical Monitor |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
Wyeth is now a wholly owned subsidiary of Pfizer |
|
Name:
|
Trial Manager |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
For Poland, WVWZMED@wyeth.com |
|
Name:
|
Trial Manager |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
For Finland, Sweden, MedInfoNord@wyeth.com |
|
Name:
|
Trial Manager |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
For Ukraine, Romania, WPVIMED@wyeth.com |
|
Name:
|
Trial Manager |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
For Belgium, trials-BEL@wyeth.com |
|
Name:
|
Trial Manager |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
For Czech Republic, WPPGCLI@wyeth.com |
|
Name:
|
Trial Manager |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
For Mexico, gomezlj@wyeth.com |
|
Name:
|
Trial Manager |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
For Netherlands, trials-NL@wyeth.com |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Postmenopausal women of age 40 to 65 seeking treatment for hot flashes with last
natural menstrual period (LNMP) completed at least 12 months prior to screening.
- Minimum of 7 moderate to severe hot flashes per day or 50 per week recorded for 7
consecutive days
- Body Mass Index less than or equal to 34 kg/m2 using the nomograph for BMI.
Exclusion Criteria:
- History, presence, or suspicion of estrogen-dependent neoplasia; Malignancy, or
treatment for malignancy, within the previous 2 years.
- Active or recent arterial thromboembolic disease; History of venous thromboembolism
- History of cerebrovascular accident, stroke, or transient ischemic attack -
- Presence of major depressive disorder, bipolar disorder, psychotic disorder, or
generalized anxiety disorder requiring therapy
- Persistent elevated blood pressure
Age minimum:
40 Years
Age maximum:
65 Years
Gender:
Female
|
Health Condition(s) or Problem(s) studied
|
Menopause
|
Intervention(s)
|
Drug: DVS-233
|
Primary Outcome(s)
|
To assess the efficacy and safety of DVS-233 SR compared with placebo for treatment of vasomotor symptoms (VMS) associated with menopause and to compare the bleeding incidence of DVS-233 SR and tibolone.
|
Secondary Outcome(s)
|
To assess the effects of DVS-233 SR and tibolone on changes from baseline in weight, breast pain, and health outcomes indicators.
|
Secondary ID(s)
|
3151A2-321
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|